论文部分内容阅读
目的探讨EphA2受体及其配体EphrinA1在乳腺浸润性导管癌组织中的表达及其临床意义。方法应用免疫组织化学和原位杂交方法检测EphA2和EphrinA1在30例乳腺纤维瘤、30例乳腺囊性增生和100例乳腺浸润性导管癌组织中的表达,分析其表达水平与临床病理特征的关系以及二者间表达的相关性。结果 (1)免疫组织化学方法和原位杂交法均检测到EphA2及其配体EphrinA1蛋白和mRNA在乳腺浸润性导管癌组织中的表达均分别明显高于其在乳腺囊性增生组织(P<0.001)和乳腺纤维瘤组织(P<0.001)中的表达。(2)EphA2和EphrinA1蛋白和mRNA表达均与乳腺浸润性导管癌患者的淋巴结转移、组织学分级和TNM分期有关(P<0.05),即在有淋巴结转移、组织学分级较高及TNM分期较晚的乳腺浸润性导管癌组织中EphA2和EphrinA1蛋白和mRNA表达阳性率均较高;然而二者的表达与乳腺浸润性导管癌患者的年龄和肿瘤直径无关(P>0.05)。(3)乳腺浸润性导管癌组织中EphA2与EphrinA1蛋白表达阳性率呈正相关(rs=0.999,P<0.01),EphA2与EphrinA1 mRNA表达阳性率也呈正相关(rs=0.942,P<0.01)。结论 EphA2和EphrinA1的表达可能与乳腺浸润性导管癌的发生、发展有一定的关系,对其联合检测可能对乳腺浸润性导管癌的生物学特征和预后判断具有一定的指导性意义,可能为今后的临床用药、预测预后和靶向治疗提供新的靶点。
Objective To investigate the expression of EphA2 receptor and its ligand EphrinA1 in breast invasive ductal carcinoma and its clinical significance. Methods The expressions of EphA2 and EphrinA1 in 30 cases of breast fibroadenoma, 30 cases of breast cystic hyperplasia and 100 cases of invasive ductal breast carcinoma were detected by immunohistochemistry and in situ hybridization. The relationship between the expression of EphA2 and EphrinA1 and the clinicopathological features was analyzed As well as the correlation between the two. Results (1) The expression of EphA2 and its ligand EphrinA1 protein and mRNA in breast invasive ductal carcinomas were significantly higher than those in cystic mastocyst (P <0.01) by immunohistochemistry and in situ hybridization 0.001) and breast fibroma (P <0.001). (2) The expression of EphA2 and EphrinA1 protein and mRNA were correlated with lymph node metastasis, histological grade and TNM stage in patients with invasive ductal carcinoma (P <0.05), that is, with lymph node metastasis, higher histological grade and TNM stage The positive rates of EphA2 and EphrinA1 protein and mRNA were higher in late breast invasive ductal carcinoma tissues, however, the expression of EphA2 and EphrinA1 protein was not correlated with the age and tumor diameter of invasive ductal carcinoma (P> 0.05). (3) The positive rates of EphA2 and EphrinA1 in breast invasive ductal carcinoma were positively correlated (rs = 0.999, P <0.01). The positive rates of EphA2 and EphrinA1 were also positively correlated (rs = 0.942, P <0.01). Conclusions The expression of EphA2 and EphrinA1 may be related to the occurrence and development of invasive ductal carcinoma of the breast. The combined detection of EphA2 and EphrinA1 may be of guiding significance for the biological characteristics and prognosis of invasive ductal carcinoma of the breast. Clinical treatment, prognosis and targeted therapy to provide a new target.